Skip to main content
Equibles
PRGO logo

PRGO · PERRIGO Co plc · Documents

Track PRGO — free

Use PRGO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRGO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.70 -0.13 (-0.82%) Play latest call Q3 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.18B
Shares
138.80M
Volume · Nov 5 2.87M Avg daily vol (3M) 2.64M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $4.25B down 2.8% 10-K filed Feb 26, 2026 Quarterly report New FY2026 Q3 Revenue $988.6M down 5.2% 10-Q filed Nov 4, 2026 Latest results New Infant Formula sale planned as adjusted earnings decline 8-K filed Nov 4, 2026 Earnings call New Q3 2026 earnings call Held Nov 4, 2026
2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 26
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $988.6M ▼ 5.2% Net loss $27.5M Diluted EPS -$0.20
Nov 4
Current report 8-K
Infant Formula sale planned as adjusted earnings decline

Perrigo Company plc reported Core adjusted diluted EPS of $0.61, down 9.0%, and agreed to divest Infant Formula for up to $175 million. The company expects a $275.0 million to $375.0 million impairment loss during the fourth quarter of 2026.

Financial results
4 source passages
Perrigo Company plc (NYSE: PRGO) Core adjusted EPS declined $0.06 to $0.61, a 9.0% decrease from the prior year. Subsequent to quarter-end, the Company announced an agreement to divest its Infant Formula business for total consideration of up to $175 million. After considering expected carrying value relative to cash proceeds and an estimate of fair value of the contingent milestones, we expect to recognize an impairment loss between $275.0 million and $375.0 million resulting from the measurement as held for sale during the fourth quarter of 2026. Open the document at this passage
Oct 29
Current report 8-K
Regulation FD disclosure

Perrigo entered a definitive agreement for MeridianMade to acquire its Infant Formula business for total consideration of up to $175 million, including $40 million cash at closing and up to $135 million in contingent payments. Closing is expected in the first half of 2027.

Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 27
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.02B ▼ 3.2% Net income $74.5M Diluted EPS $0.53
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 28
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $969.2M ▼ 7.2% Net loss $398.6M Diluted EPS -$2.87
Mar 20
Proxy statement DEF 14A Meeting Apr 30, 2026
Proxy statement AI summary on its way
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $4.25B ▼ 2.8% Net loss $1.43B Diluted EPS -$10.29
2025
Feb 28
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $4.37B ▼ 6.1% Net loss $171.8M Diluted EPS -$1.25
Showing 1–50 of 183 documents
Key facts CIK 1585364 CUSIP G97822103 13F (30d) 129 filings 118 filers Visit website Investor relations